GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 16, 2016
- Accepted in final form August 8, 2016
- First Published September 8, 2016.
Author Disclosures
- Victoria Mallett,
- Jay P. Ross, BSc,
- Roy N. Alcalay, MD, MSc,
- Amirthagowri Ambalavanan, MSc,
- Ellen Sidransky, MD,
- Patrick A. Dion, PhD,
- Guy A. Rouleau, MD, PhD and
- Ziv Gan-Or, MD, PhD
- Victoria Mallett,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jay P. Ross, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Canada Graduate Scholarship CGS M - Canadian Institutes for Health Research (CIHR).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roy N. Alcalay, MD, MSc,
NONE
NONE
consultation fees from Genzyme/Sanofi and prophase
NONE
NONE
NONE
NONE
Consultation for Genzyme/Sanofi and Prophase
NONE
NONE
NONE
NONE
NIH K02NS080915
NONE
1. The Brookdale Foundation 2. The Michael J Fox Foundation 3. Parkinson's Disease Foundation 4. The Smart Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Amirthagowri Ambalavanan, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ellen Sidransky, MD,
Medical Advisory Board- National Gaucher Foundation
NONE
NONE
Molecular genetics and Metabolism- Editorial Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Merck
This work is funded by the intramural research program of the NHGRI and NIH
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick A. Dion, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Guy A. Rouleau, MD, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) CIHR Foundation Scheme (FDN-143260); 07/2015 to 06/2022; 708,381$/year. Genetic & Biological Studies of Brain Disorders. Role: Principal Applicant (2) ALS Society of Canada, 09/2013 to 08/2015. Assessment of somatic mutations and repeat instability in known ALS genes. Role: Principal Applicant. (3) ALS Association (OJ3X54), 08/2012 to 07/2015. Characterization of C9ORF72 expansion stability in ALS/FTD patients. Role: Principal Applicant.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ziv Gan-Or, MD, PhD
NONE
NONE
Sanofy/genzyme, travel fees and speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Canadian Institute of Health Research, Post-doctoral fellowship, post-doctoral fellow, 2014-2016
(1) McGill University
(1) Michael J. Fox Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Montreal Neurological Institute (V.M., J.P.R., A.A., P.A.D., G.A.R., Z.G.-O.), Department of Human Genetics (J.P.R., A.A., G.A.R., Z.G.-O.), Department of Neurology and Neurosurgery (P.A.D., G.A.R., Z.G.-O.), McGill University, Quebec, Canada; Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain (R.N.A.), College of Physicians and Surgeons, Columbia University, New York, NY; and Section on Molecular Neurogenetics (E.S.), Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.
- Correspondence to Dr. Gan-Or: ziv.gan-or{at}mail.mcgill.ca
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Differential effects of severe vs mild GBA mutations on Parkinson diseaseZiv Gan-Or, Idan Amshalom, Laura L. Kilarski et al.Neurology, February 04, 2015 -
Articles
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onsetZ. Gan-Or, N. Giladi, U. Rozovski et al.Neurology, April 23, 2008 -
Article
β-Glucocerebrosidase activity in GBA-linked Parkinson diseaseThe type of mutation mattersYoung Eun Huh, Ming Sum Ruby Chiang, Joseph J. Locascio et al.Neurology, June 15, 2020 -
Article
GBA variants in REM sleep behavior disorderA multicenter studyLynne Krohn, Jennifer A. Ruskey, Uladzislau Rudakou et al.Neurology, June 26, 2020